GMS FINAL A PRACTICE EXAMINATION
2026 QUESTIONS WITH ANSWERS
GRADED A+
◍ What is informed consent in the context of research?.
Answer: Informed consent in research refers to the voluntary agreement
made by an individual to participate in a study or trial after receiving
essential information that enables them to make an informed decision.
◍ What is voluntarism in the context of informed consent?.
Answer: Voluntarism refers to the voluntary decision made by an individual
to participate in a research trial without any form of coercion. It emphasizes
the importance of individuals being able to evaluate the potential benefits
and risks of the trial independently and freely.
◍ What is selectivity in drug targeting?.
Answer: Refers to a drug's ability to specifically interact with its intended
target while minimizing interactions with other molecules in the body.
◍ Q1: What is the purpose of prevention trials?.
Answer: A1: Prevention trials aim to identify approaches to reduce the risk
of developing specific diseases or conditions.
◍ Why is it important to select patients with similar characteristics for clinical
trials?.
Answer: Helps make the study results more accurate and applicable.
◍ What is the purpose of exclusion criteria in clinical studies?.
Answer: Used to disqualify individuals from participating in a clinical study.
They aim to exclude patients who may not benefit from the therapy or could
be harmed by it.
,◍ Q: What does "unmet health needs" refer to?.
Answer: A: Conditions or requirements for healthcare not adequately
addressed by current services, treatments, or interventions.
◍ Q1: What is the role of the FDA in regulating biologics?.
Answer: A1: The FDA oversees the regulation and approval of biologics in
the United States, ensuring their safety, efficacy, and quality through
regulatory oversight.
◍ What is the process of absorption in pharmacokinetics?.
Answer: The process by which a drug enters the bloodstream from its site of
administration.
◍ What are inclusion and exclusion criteria in patient selection for a clinical
trial?.
Answer: Inclusion criteria are the things patients need to have to be part of
the study, while exclusion criteria are the things that would prevent them
from participating.
◍ Q: What are alternatives to relying solely on the maximum tolerated dose
(MTD) in Phase I trials?.
Answer: A: Measure target engagement, monitor relevant plasma drug
levels, and identify surrogate markers of target engagement in non-target
tissues.
◍ Why is it important to consider the mechanism of action when defining
inclusion criteria?.
Answer: Understanding the mechanism of action helps identify patients who
are most likely to benefit from the therapy being studied, ensuring the trial
focuses on the appropriate population.
◍ What does it mean for the protocol to work in the context of a clinical trial?.
Answer: It refers to the plan of research outlining the study's specific
procedures and assessments.
◍ Q: What is the primary objective of Phase 0 trials?.
Answer: A: The primary objective of Phase 0 trials is not to provide
, therapeutic benefit but to collect data on drug pharmacokinetics and target
engagement.
◍ What is pharmacokinetics?.
Answer: The study of how a drug is absorbed, distributed, metabolized, and
eliminated by the body.
◍ What is the goal of T3 research?.
Answer: To implement new therapies or diagnostic tools into clinical
practice and evaluate their effectiveness in real-world settings.
◍ What is the chemical name of a drug?.
Answer: Describes its chemical structure and composition following specific
rules of chemical nomenclature.
◍ What are some of the advantages of using animal models in pre-clinical
research?.
Answer: The ability to control experimental conditions, the ability to study
complex biological systems, and the ability to evaluate the safety and
efficacy of new therapies or diagnostic tools in a living organism.
◍ Q: Why do researchers use different in vivo pre-clinical cancer models?.
Answer: A: Researchers choose different in vivo pre-clinical cancer models
based on their research goals, cancer type, and desired outcomes, as each
model has specific advantages and limitations.
◍ Q2: What is the main objective of Phase III trials?.
Answer: A2: The main objective of Phase III trials is to gather more
extensive information about the safety and effectiveness of the drug by
studying larger populations, different dosages, and potential combinations
with other drugs. These trials provide critical evidence for regulatory
approval and further support the drug's efficacy.
◍ Q: Why is it important to justify the need for a clinical trial?.
Answer: A: Justification provides a scientific rationale for the trial,
explaining its necessity and how it relates to existing treatments for the
targeted disease or condition.
, ◍ What are inclusion criteria in clinical studies?.
Answer: The characteristics required for individuals to be included in a
clinical study. They help identify those who are likely to benefit from the
therapy being tested.
◍ Why is it important to consider resources and time frame when defining the
objectives of a clinical trial study?.
Answer: Considering resources and time frame ensures that the study
objectives can be achieved within the available resources and specified
timeline, allowing for effective study conduct and reliable results.
◍ Q: How can the FDA address delays in drug availability?.
Answer: A: Implement "fast-tracking" measures to expedite the regulatory
process.
◍ Q: How can the traditional Phase I trial design delay the availability of
life-saving drugs?.
Answer: A: The cautious dose escalation and safety evaluation process in
traditional Phase I trials can prolong the time it takes for a drug to progress
through subsequent phases of clinical development, leading to delays in
making potentially life-saving drugs available to patients.
◍ Q: What does it mean for a drug to affect the structure or function of the
body?.
Answer: A: When a drug affects the structure or function of the body, it
implies that the substance interacts with biological processes or modifies
physiological functions.
◍ Q: How do standalone tests differ from a series of tests?.
Answer: A: Standalone tests are conducted independently, while a series of
tests involves multiple tests performed sequentially or in combination.
◍ Q: How should the trial design be described in the protocol?.
Answer: A: The overall design of the trial should be explained, such as
whether it is a randomized controlled trial, observational study, or other type
of study design. Details on the allocation of participants to different
2026 QUESTIONS WITH ANSWERS
GRADED A+
◍ What is informed consent in the context of research?.
Answer: Informed consent in research refers to the voluntary agreement
made by an individual to participate in a study or trial after receiving
essential information that enables them to make an informed decision.
◍ What is voluntarism in the context of informed consent?.
Answer: Voluntarism refers to the voluntary decision made by an individual
to participate in a research trial without any form of coercion. It emphasizes
the importance of individuals being able to evaluate the potential benefits
and risks of the trial independently and freely.
◍ What is selectivity in drug targeting?.
Answer: Refers to a drug's ability to specifically interact with its intended
target while minimizing interactions with other molecules in the body.
◍ Q1: What is the purpose of prevention trials?.
Answer: A1: Prevention trials aim to identify approaches to reduce the risk
of developing specific diseases or conditions.
◍ Why is it important to select patients with similar characteristics for clinical
trials?.
Answer: Helps make the study results more accurate and applicable.
◍ What is the purpose of exclusion criteria in clinical studies?.
Answer: Used to disqualify individuals from participating in a clinical study.
They aim to exclude patients who may not benefit from the therapy or could
be harmed by it.
,◍ Q: What does "unmet health needs" refer to?.
Answer: A: Conditions or requirements for healthcare not adequately
addressed by current services, treatments, or interventions.
◍ Q1: What is the role of the FDA in regulating biologics?.
Answer: A1: The FDA oversees the regulation and approval of biologics in
the United States, ensuring their safety, efficacy, and quality through
regulatory oversight.
◍ What is the process of absorption in pharmacokinetics?.
Answer: The process by which a drug enters the bloodstream from its site of
administration.
◍ What are inclusion and exclusion criteria in patient selection for a clinical
trial?.
Answer: Inclusion criteria are the things patients need to have to be part of
the study, while exclusion criteria are the things that would prevent them
from participating.
◍ Q: What are alternatives to relying solely on the maximum tolerated dose
(MTD) in Phase I trials?.
Answer: A: Measure target engagement, monitor relevant plasma drug
levels, and identify surrogate markers of target engagement in non-target
tissues.
◍ Why is it important to consider the mechanism of action when defining
inclusion criteria?.
Answer: Understanding the mechanism of action helps identify patients who
are most likely to benefit from the therapy being studied, ensuring the trial
focuses on the appropriate population.
◍ What does it mean for the protocol to work in the context of a clinical trial?.
Answer: It refers to the plan of research outlining the study's specific
procedures and assessments.
◍ Q: What is the primary objective of Phase 0 trials?.
Answer: A: The primary objective of Phase 0 trials is not to provide
, therapeutic benefit but to collect data on drug pharmacokinetics and target
engagement.
◍ What is pharmacokinetics?.
Answer: The study of how a drug is absorbed, distributed, metabolized, and
eliminated by the body.
◍ What is the goal of T3 research?.
Answer: To implement new therapies or diagnostic tools into clinical
practice and evaluate their effectiveness in real-world settings.
◍ What is the chemical name of a drug?.
Answer: Describes its chemical structure and composition following specific
rules of chemical nomenclature.
◍ What are some of the advantages of using animal models in pre-clinical
research?.
Answer: The ability to control experimental conditions, the ability to study
complex biological systems, and the ability to evaluate the safety and
efficacy of new therapies or diagnostic tools in a living organism.
◍ Q: Why do researchers use different in vivo pre-clinical cancer models?.
Answer: A: Researchers choose different in vivo pre-clinical cancer models
based on their research goals, cancer type, and desired outcomes, as each
model has specific advantages and limitations.
◍ Q2: What is the main objective of Phase III trials?.
Answer: A2: The main objective of Phase III trials is to gather more
extensive information about the safety and effectiveness of the drug by
studying larger populations, different dosages, and potential combinations
with other drugs. These trials provide critical evidence for regulatory
approval and further support the drug's efficacy.
◍ Q: Why is it important to justify the need for a clinical trial?.
Answer: A: Justification provides a scientific rationale for the trial,
explaining its necessity and how it relates to existing treatments for the
targeted disease or condition.
, ◍ What are inclusion criteria in clinical studies?.
Answer: The characteristics required for individuals to be included in a
clinical study. They help identify those who are likely to benefit from the
therapy being tested.
◍ Why is it important to consider resources and time frame when defining the
objectives of a clinical trial study?.
Answer: Considering resources and time frame ensures that the study
objectives can be achieved within the available resources and specified
timeline, allowing for effective study conduct and reliable results.
◍ Q: How can the FDA address delays in drug availability?.
Answer: A: Implement "fast-tracking" measures to expedite the regulatory
process.
◍ Q: How can the traditional Phase I trial design delay the availability of
life-saving drugs?.
Answer: A: The cautious dose escalation and safety evaluation process in
traditional Phase I trials can prolong the time it takes for a drug to progress
through subsequent phases of clinical development, leading to delays in
making potentially life-saving drugs available to patients.
◍ Q: What does it mean for a drug to affect the structure or function of the
body?.
Answer: A: When a drug affects the structure or function of the body, it
implies that the substance interacts with biological processes or modifies
physiological functions.
◍ Q: How do standalone tests differ from a series of tests?.
Answer: A: Standalone tests are conducted independently, while a series of
tests involves multiple tests performed sequentially or in combination.
◍ Q: How should the trial design be described in the protocol?.
Answer: A: The overall design of the trial should be explained, such as
whether it is a randomized controlled trial, observational study, or other type
of study design. Details on the allocation of participants to different
